4,025 results match your criteria Plaque Psoriasis


Efficacy of secukinumab without the initial weekly loading dose in patients with chronic plaque psoriasis.

Br J Dermatol 2019 Apr 20. Epub 2019 Apr 20.

Section of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy.

Background: Secukinumab is administered at the labelled dose of 300 mg at weeks 0, 1, 2, 3, 4 (loading dose) and every 4 weeks thereafter.

Objective: To investigate the efficacy of secukinumab administered without the initial loading dose in patients with psoriasis.

Materials And Methods: a retrospective, observational study including adult patients with psoriasis (n=156) treated with secukinumab 300 mg administered either according to the labelled dose (n=75) or without the initial loading dose (n=81). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18015DOI Listing

Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab.

J Eur Acad Dermatol Venereol 2019 Apr 18. Epub 2019 Apr 18.

Department of Dermatology, Toulouse University, Hôpital Larrey, Toulouse, France.

Clinical studies have the shown rapid efficacy biological agents targeting anti-IL17 in patients with moderate to severe plaque psoriasis. However, preliminary data from the Danish registry DERMBIO showed a significant loss of efficacy with secukinumab. This was a retrospective study of 14 patients treated with secukinumab for moderate-to-severe psoriasis who had an incomplete initial response or who experienced a loss of efficacy with secukinumab and who were subsequently treated with ixekizumab. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15630DOI Listing

Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study.

Br J Dermatol 2019 Apr 18. Epub 2019 Apr 18.

Dermatology Unit, Department of Biomedical Sciences, Humanitas University, Via Alessandro Manzoni 113, 20089, Rozzano-Milan, Italy.

Recent studies have shown that biological drugs approved for treating psoriasis and psoriatic arthritis are not effective in all patients, and that variations in the genome have been associated with different clinical responses or side effects. HLA-Cw6 gene is associated with more severe and early-onset psoriasis. Recent reports have shown that HLA-Cw6 status predicts efficacy of some biologic treatments in psoriasis patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18013DOI Listing

Lp- PLA2 as a promising predictor of comorbidities in patients with severe psoriasis.

J Dermatolog Treat 2019 Apr 18:1-27. Epub 2019 Apr 18.

a Department of Dermatology and Venereology Medical University of Bialystok , 15-540 Bialystok, Zurawia 14 St , Poland.

Objective: Lipoprotein-associated phospholipase A2 (Lp-PLA2) is a well- known risk factor of atherosclerotic vascular diseases which are common comorbidities in psoriasis. The aim of this study was to evaluate serum Lp-PLA2 level in psoriatic patients and elucidate possible associations with disease activity, metabolic or inflammatory parameters and systemic treatment.

Methods: We enrolled 33 patients with active plaque-type psoriasis and 11 healthy controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1606887DOI Listing

The efficacy and safety of targeted narrowband UVB therapy: a retrospective cohort study

Turk J Med Sci 2019 Apr 18;49(2):595-603. Epub 2019 Apr 18.

Background/aim: Phototherapy is a safe and effective treatment modality for numerous dermatological conditions. Recently, targeted phototherapy modalities have gained importance due to their advantages over conventional phototherapy.This retrospective study aimed to evaluate the safety and efficacy of targeted narrowband UVB phototherapy in patients with dermatological disorders

Materials And Methods: This single-center study included 173 patients who were treated with targeted narrowband UVB phototherapy. Read More

View Article

Download full-text PDF

Source
http://online.journals.tubitak.gov.tr/openDoiPdf.htm?mKodu=s
Publisher Site
http://dx.doi.org/10.3906/sag-1810-110DOI Listing
April 2019
1 Read

Association of HLA-C*06:02 Status With Differential Response to Ustekinumab in Patients With Psoriasis: A Systematic Review and Meta-analysis.

JAMA Dermatol 2019 Apr 17. Epub 2019 Apr 17.

Department of Dermatology, Radboud University Medical Centre, Radboud Institute of Health Sciences, Nijmegen, the Netherlands.

Importance: Previous research showed a differential response to ustekinumab therapy based on HLA-C*06:02 status in patients with psoriasis but consisted mostly of small (and sometimes inconclusive) cohort studies.

Objective: To assess whether HLA-C*06:02 status is associated with a differential response to ustekinumab therapy in patients with psoriasis through a systematic review and a meta-analysis of available data.

Data Sources: A comprehensive search was conducted using MEDLINE, Embase, the Cochrane Library, Web of Science, and gray literature sources. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1001/jamadermatol.2019.0098DOI Listing

Vitiligo in a patient receiving infliximab for chronic plaque psoriasis.

Dermatol Ther 2019 Apr 17:e12917. Epub 2019 Apr 17.

Department of Dermatology, Shanghai Skin Disease Hospital, 1278 Baode Road, Shanghai 200443, China.

Infliximab is a TNF-a Inhibitor widely used in the treatment of moderate to severe chronic plaque psoriasis. Here, we report a case of vitiligo following infliximab administration in a patient with chronic plaque psoriasis. The case serves as a reminder of vitiligo induced by TNF-a-antagonist therapy. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/dth.12917
Publisher Site
http://dx.doi.org/10.1111/dth.12917DOI Listing
April 2019
3 Reads

Liver fatty acid-binding protein might be a predictive marker of clinical response to systemic treatment in psoriasis.

Arch Dermatol Res 2019 Apr 16. Epub 2019 Apr 16.

Department of Dermatology and Venereology, Medical University of Bialystok, Zurawia 14 St, 15-540, Białystok, Poland.

Fatty acid-binding proteins play an inconclusive role in lipid metabolism and cardiometabolic diseases (CMDs) which are closely related with psoriasis. Aim of the study was to investigate the diagnostic value of serum liver fatty acid-binding protein (FABP1) level and associations with disease severity, inflammation or metabolic parameters and influence of systemic treatment in psoriatic patients. The study included thirty-three patients with active plaque-type psoriasis and eleven healthy volunteers. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00403-019-01917-wDOI Listing
April 2019
1 Read

Mechanisms of microbial pathogenesis and the role of the skin microbiome in psoriasis: A review.

Clin Dermatol 2019 Mar - Apr;37(2):160-166. Epub 2019 Jan 16.

Center for Dermatology Research, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA; Departments of Pathology and Social Sciences & Health Policy, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.

The pathogenesis of psoriasis may involve a breakdown of immune tolerance to cutaneous microorganisms. Psoriasis is associated with a higher incidence of Crohn disease and periodontitis, two diseases involving impaired tolerance and abnormal immune activation in response to intestinal and oral microbiota, respectively. In addition, guttate and chronic plaque psoriasis are associated with Streptococcus pyogenes colonization. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.clindermatol.2019.01.011DOI Listing
January 2019
2 Reads

Successful response of genital psoriasis to ixekizumab: report of 6 cases.

J Eur Acad Dermatol Venereol 2019 Apr 13. Epub 2019 Apr 13.

Department of Dermatology, Consorci Hospital General Universitari de Valencia.

Psoriasis is a chronic inflammatory disease affecting up to 2-3% of the population worldwide . Genital psoriasis (GenPs) is a frequent, debilitating, stigmatizing and difficult-to-treat manifestation of plaque psoriasis. Literature is scarce on controlled trials dedicated to the management and effective treatment of this special localization . Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jdv.15623
Publisher Site
http://dx.doi.org/10.1111/jdv.15623DOI Listing
April 2019
1 Read

Drug survival of biological therapy is showing class effect: updated results from Slovenian National Registry of psoriasis.

Int J Dermatol 2019 Apr 11. Epub 2019 Apr 11.

Department of Dermatovenereology, University Medical Centre Maribor, Maribor, Slovenia.

Background: Drug survival is an important measure of successful treatment of patients with chronic diseases such as psoriasis. Therefore, the objective was to calculate drug survival and examine safety profile of biologics and immunomodulators (adalimumab, apremilast, etanercept, ixekizumab, infliximab, secukinumab, and ustekinumab) from the Slovenian National Registry of patients with moderate-to-severe psoriasis.

Methods: Data about the patients with moderate-to-severe plaque psoriasis treated with biologics were collected from 2005 until July 2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/ijd.14429DOI Listing

Prevalence of cutaneous comorbidities in psoriatic patients and their impact on quality of life.

Eur J Dermatol 2019 Apr 10. Epub 2019 Apr 10.

Dermatology Department, Catholic University of the Sacred Heart, Rome.

In contrast to the evidence for systemic co-morbidities, relatively few studies have examined the prevalence of cutaneous inflammatory co-morbidities in psoriatic patients. We conducted an observational multi-site study to measure the prevalence of cutaneous co-morbidities in adult patients with plaque psoriasis and to assess the relative impact on quality of life (QOL). Each patient attending one of the study clinics over a period of six months was evaluated to assess the presence of any concomitant skin inflammatory disease other than psoriasis at the time of the visit. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1684/ejd.2019.3529DOI Listing
April 2019
2 Reads

Development of clinical diagnostic criteria for plaque psoriasis in children: An eDelphi consensus study with the International Psoriasis Council.

Br J Dermatol 2019 Apr 10. Epub 2019 Apr 10.

Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK.

Psoriasis in children can be a challenging diagnosis: the clinical presentation is often more subtle, may occur in covered sites and can be an unexpected diagnosis as psoriasis if often thought to occur at older ages. Poor recognition and delayed diagnosis of psoriasis in children can lead to inadequate treatment and lack of monitoring for comorbidities including juvenile psoriatic arthritis. Diagnostic criteria would help both clinical practice and clinical research, but to date none are available. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17994DOI Listing
April 2019
1 Read

Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous Th1- and Th17-inflammatory pathways.

Br J Dermatol 2019 Apr 10. Epub 2019 Apr 10.

Dermatological Sciences, University of Manchester, Manchester, UK.

Methotrexate (MTX) is one of the most frequently used conventional systemic therapies for the treatment of moderate to severe plaque-type psoriasis. Although it has been available since the 1950s (1), its exact mechanism of action in the treatment of chronic inflammatory skin conditions remains to be fully determined. Clinical studies indicate good clinical responses (Psoriasis Area and Severity Index, PASI 75) in approximately 40% of patients with psoriasis and clinical effects peak after approximately 16 weeks of therapy (2, 3, 4). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.18001DOI Listing
April 2019
1 Read

The Challenge of Variable Costs in Decisions Based on Cost-Effectiveness Evidence: A Case Study for Brodalumab.

Am Health Drug Benefits 2019 Feb;12(1):22-26

Professor of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC.

Background: Payers often consider cost-effectiveness studies for new drugs when making decisions on coverage, formulary position, and budgets; however, cost-effectiveness studies are often calculated using estimated pricing before a drug's launch. If the drug's price changes on or after launch, or if rebate programs are initiated, cost-effectiveness studies need to be updated to prevent payers from making decisions using inaccurate value assumptions, which can lead to unexpected financial impacts and potentially delay patient access to drugs.

Objective: To evaluate how lower at-launch drug pricing versus initial estimated pricing affects cost-effectiveness ratios and potentially influences treatment decisions, using the case study of brodalumab, a biologic drug indicated for the treatment of moderate-to-severe plaque psoriasis. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6404800PMC
February 2019

Ustekinumab treatment for moderate to severe psoriasis. Eight-year real-world follow-up of 61 cases in a tertiary level hospital.

J Dermatolog Treat 2019 Apr 8:1-20. Epub 2019 Apr 8.

b Department of Dermatology , Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas, Instituto de Investigación Biomédica de A Coruña (INIBIC), Universidade da Coruña (UDC) , Spain.

Background Efficacy and safety profiles of ustekinumab have been proved in numerous clinical trials. However, relevant variations with daily practice have been shown, and few studies value the long-term response maintenance. Objective To evaluate the efficacy of long-term ustekinumab therapy in patients with moderate-to-severe plaque-type psoriasis in a real-world setting. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1605140DOI Listing

Long-term effects of biologic therapies on peripheral blood eosinophils in patients with psoriasis: A 3-year single-centre study.

J Dermatolog Treat 2019 Apr 8:1-20. Epub 2019 Apr 8.

a Department of Dermatology and Venereology , Hacettepe University, School of Medicine , Ankara , Turkey.

Background: Biologic therapies (BTs),etanercept, infliximab, adalimumab, ustekinumab, are generally well-tolerated and safe agents in psoriasis management.

Objectives: To determine the overall effect of BTs on peripheral blood eosinophil count(PBEc) and percentage(PBEp), peripheral blood basophil count(PBBc) and percentage(PBBp), white blood cell count(WBCc),erythrocyte sedimentation rate(ESR),and serum C-reactive protein(s-CRP) level during a 3-year follow-up in patients with psoriasis.

Methods: This retrospective cohort study included 200 patients(116 men;84 women) treated continuously with BTs for 3 years for plaque-type, pustular, or nail psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1605139DOI Listing
April 2019
1 Read

Non-antistreptococcal interventions for acute guttate psoriasis or an acute guttate flare of chronic psoriasis.

Cochrane Database Syst Rev 2019 Apr 8;4:CD011541. Epub 2019 Apr 8.

Department of Dermatology, Université François-Rabelais de Tours, Tours, France, 37044.

Background: Guttate psoriasis displays distinctive epidemiological and clinical features, making it a separate entity within the heterogeneous group of cutaneous psoriasis types. It is associated with genetic, immune, and environmental factors (such as stress and infections) and usually arises in younger age groups (including children, teenagers, and young adults). There is currently no cure for psoriasis, but various treatments can help to relieve the symptoms and signs. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/14651858.CD011541.pub2DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6452774PMC

Favorable response to apremilast in a patient with refractory psoriasis verrucosa.

J Dermatol 2019 Apr 8. Epub 2019 Apr 8.

Department of Dermatology, Kochi Medical School, Kochi University, Nankoku, Japan.

A 67-year-old man, who had been diagnosed with psoriasis 30 years prior, visited our hospital with a complaint of verrucous nodules in the lower legs, which had developed 15 years previously. We diagnosed him as having psoriasis verrucosa of the legs and plaque psoriasis of the torso. Because the lesions were resistant to topical glucocorticoids and vitamin D , a verrucous lesion in the right leg was treated with surgical ablation, which resulted in the development of generalized pustular psoriasis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/1346-8138.14877DOI Listing
April 2019
1 Read

Review on Characteristics and Analytical Methods of Tazarotene: An Update.

Crit Rev Anal Chem 2019 Apr 3:1-7. Epub 2019 Apr 3.

a School of Pharmacy and Technology Management , NMIMS , Shirpur , Maharashtra , India.

Tazarotene (TZR) is the first topical receptor-selective retinoid prodrug derived from vitamin A used for management of plaque psoriasis and efficacious in dealing of acne vulgaris, and photo aging. As per US food and drug administration (FDA), 0.1% strength of TZR is permitted for the treatment of acne. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10408347.2019.1586519DOI Listing
April 2019
3 Reads

Evaluation of Toll-like receptor expression profile in patients with psoriasis vulgaris.

Gene 2019 Mar 29;702:166-170. Epub 2019 Mar 29.

Department of Medical Biology, Bozok University School of Medicine, Yozgat, Turkey. Electronic address:

TLRs are thought to play a role in the pathophysiology of such dermatological diseases as leprosy, acne and psoriasis. The study included 20 patients with plaque psoriasis, as well as 20 healthy age- and gender-matched control subjects. Real-time polymerase chain reaction evaluation was made of the messenger RNA expression of TLRs 1-10 in lesional tissue and peripheral blood mononuclear cell samples in psoriasis patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.gene.2019.03.058DOI Listing
March 2019
5 Reads

Off-label studies on apremilast in dermatology: a review.

J Dermatolog Treat 2019 Apr 2:1-10. Epub 2019 Apr 2.

a Division of Dermatology, Department of Medicine , David Geffen School of Medicine at UCLA , Los Angeles , CA , USA.

Purpose: Apremilast is a phosphodiesterase-4 inhibitor FDA approved for psoriatic arthritis and moderate to severe plaque psoriasis. In recent years, multiple studies have suggested other potential uses for apremilast in dermatology. A summary of these various studies will be a valuable aid to dermatologists considering apremilast for an alternative indication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1589641DOI Listing
April 2019
5 Reads

Switching from Secukinumab to Ustekinumab in Psoriasis Patients: Results from a Multicenter Experience.

Dermatology 2019 Mar 29:1-6. Epub 2019 Mar 29.

Dermatology Unit, Azienda Ospedaliera San Donato Milanese, Milan, Italy.

Background: Switching between biologics is commonly performed for the management of plaque psoriasis. However, no evidence about switching from secukinumab to ustekinumab has been reported.

Methods: This retrospective observational multicenter study aimed to describe efficacy and safety of ustekinumab in secukinumab nonresponder patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000497274DOI Listing
March 2019
1 Read

A randomized, double-blind, placebo-controlled phase 1 study of multiple ascending doses of subcutaneous M1095, an anti-interleukin-17A/F Nanobody, in moderate-to-severe psoriasis.

J Am Acad Dermatol 2019 Mar 26. Epub 2019 Mar 26.

The Rockefeller University, New York, NY, USA.

Background: Interleukin 17 (IL-17) is involved in the pathogenesis of psoriasis, a chronic, debilitating disease.

Objectives: To evaluate safety/tolerability, immunogenicity, pharmacokinetics/pharmacodynamics and efficacy of M1095 (ALX-0761), an anti-IL-17A/F Nanobody, in moderate-to-severe plaque psoriasis.

Methods: This multicenter, double-blind, placebo-controlled dose-escalation phase 1 study randomized 44 patients 4:1 to subcutaneous M1095 (30, 60, 120, or 240 mg) or placebo bi-weekly for 6 weeks, in 4 ascending dose cohorts. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S01909622193050
Publisher Site
http://dx.doi.org/10.1016/j.jaad.2019.03.056DOI Listing
March 2019
3 Reads

Ultrasound assessment of the keratolitic effect of a 50% urea anhydrous paste on psoriasis plaques: a prospective study.

G Ital Dermatol Venereol 2019 Mar 29. Epub 2019 Mar 29.

Dermatology Clinic, University of Catania, Catania, Italy.

Background: The keratolytic effect of urea is well-known, although the majority of the available studies rely on clinical observation only. The aim of this open trial was to evaluate, through clinical and ultrasound assessment, the efficacy and tolerability of a 50% urea anhydrous paste on hyperkeratotic psoriatic plaques.

Methods: Twenty-five patients (12M/13F; age: 35-75 years) with plaque psoriasis characterized by an evident hyperkeratotic component were enrolled. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.23736/S0392-0488.19.06190-XDOI Listing

Tildrakizumab: A Review in Moderate-to-Severe Plaque Psoriasis.

Authors:
James E Frampton

Am J Clin Dermatol 2019 Apr;20(2):295-306

Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Tildrakizumab (tildrakizumab-asmn in the USA) [Ilumetri; Ilumya™] is a humanized monoclonal antibody (mAb) that selectively targets the p19 subunit of interleukin (IL)-23, thereby inhibiting the IL-23/IL-17 axis, the signalling pathway primarily implicated in the immunopathogenesis of psoriasis. Administered subcutaneously, it is approved for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy (e.g. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40257-019-00435-9DOI Listing
April 2019
1 Read

Guselkumab for the treatment of adults with moderate to severe plaque psoriasis.

Authors:
Lluís Puig

Expert Rev Clin Immunol 2019 Mar 28:1-9. Epub 2019 Mar 28.

a Department of Dermatology, Hospital de la Santa Creu i Sant Pau , Universitat Autònoma de Barcelona , Barcelona , Spain.

Introduction: Guselkumab is a subcutaneously administered monoclonal antibody that targets the IL-23p19 cytokine subunit and has been approved by the US FDA and the EMA for the treatment of moderate-to-severe psoriasis in adult patients. Areas covered: This review outlines the pharmacologic properties, efficacy and safety of guselkumab for the treatment of moderate-to-severe plaque psoriasis in adults. Expert opinion: In clinical trials, guselkumab markedly improved disease, regardless of topographical locations and patient subpopulations, with corresponding improvements in quality of life measures, and was generally well tolerated. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1744666X.2019.1601014DOI Listing

Assessment of the effects of immunogenicity on the pharmacokinetics, efficacy and safety of tildrakizumab.

Br J Dermatol 2019 Mar 27. Epub 2019 Mar 27.

Merck& Co., Inc., Kenilworth, NJ, USA.

Background: We evaluated anti-drug antibody (ADA) development in chronic plaque psoriasis subjects from 3 clinical trials of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody (P05495, reSURFACE 1, and reSURFACE 2).

Methods: In 1400 (Weeks 12-16) and 780 (Weeks 52-64) evaluable subjects randomized to tildrakizumab 100 or 200 mg, treatment-emergent ADA positive (TE-POS) subjects were identified and characterized for neutralizing antibodies (NAb-POS). Pharmacokinetics, safety, and efficacy were evaluated by ADA status. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjd.17918DOI Listing

Population-Pharmacokinetic Modeling of Tildrakizumab (MK-3222), an Anti-Interleukin-23-p19 Monoclonal Antibody, in Healthy Volunteers and Subjects with Psoriasis.

Clin Pharmacokinet 2019 Mar 26. Epub 2019 Mar 26.

Certara USA, Inc., Princeton, NJ, USA.

Background: Tildrakizumab is an anti-interleukin-23p19 monoclonal antibody recently approved for the treatment of chronic plaque psoriasis.

Methods: This analysis characterizes the population pharmacokinetics of subcutaneous tildrakizumab and identifies covariates influencing exposure in 2098 healthy volunteers and subjects with psoriasis. Tested covariates included body weight, formulation type, sex, age, race, serum albumin, creatinine clearance, Japanese origin, prior treatment with a biologic agent, subject status (subjects with psoriasis vs. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40262-019-00743-7
Publisher Site
http://dx.doi.org/10.1007/s40262-019-00743-7DOI Listing
March 2019
6 Reads

Drug survival of secukinumab and ixekizumab for moderate-to-severe plaque psoriasis.

J Am Acad Dermatol 2019 Mar 23. Epub 2019 Mar 23.

Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.

Background: Biologics targeting interleukin-17 are increasingly being used for treatment of moderate-to-severe psoriasis, but data on drug survival for these therapies remain scarce.

Objectives: To investigate the drug survival of secukinumab and ixekizumab in a nationwide cohort of patients with psoriasis in Denmark.

Methods: Using Dermbio, we examined Danish patients receiving treatment with secukinumab or ixekizumab according to the standard in-label dosing. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.03.048DOI Listing
March 2019
1 Read

Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis

J Drugs Dermatol 2019 Mar;18(3):297-299

Recently, clinical data on 8 weeks’ once-daily treatment of localized moderate-to-severe psoriasis with a novel fixed combination halobetasol propionate 0.01%/tazarotene 0.045% (HP/TAZ) lotion were published. Read More

View Article

Download full-text PDF

Source

Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis

J Drugs Dermatol 2019 Mar;18(3):279-284.

Background: Fixed combinations are commonplace in dermatology, providing significant efficacy and tolerability benefits. In some cases, two active ingredients complement each other providing a cumulative or additive effect. In rarer cases, a synergistic effect may be seen where the sum of the two active ingredients combined action is greater than the sum of the efficacy of the constituent parts. Read More

View Article

Download full-text PDF

Source
March 2019
5 Reads

Onset of Action of Antipsoriatic Drugs for Moderate-to-Severe Plaque Psoriasis: An Update

J Drugs Dermatol 2019 Mar;18(3):229-233

Objectives: The time that drugs for moderate-to-severe psoriasis take to see a clinically meaningful improvement (TOA) is one of the most important attributes of treatment success. This study synthesizes TOA data from previously reviewed drugs and adds clinical data for tidrakizumab and certolizumab pegol for comparison. Methods: We reviewed published and presented efficacy data regarding TOA, which was defined as the time at which 25% of the sample population reached Psoriasis Area and Severity Index (PASI) 75 or the time at which the sample population reached a mean PASI 50. Read More

View Article

Download full-text PDF

Source
March 2019
4 Reads

Association of geographic tongue and fissured tongue with ABO blood group among adult psoriasis patients: a novel study from a tertiary care hospital in Saudi Arabia.

Oral Surg Oral Med Oral Pathol Oral Radiol 2019 Feb 7. Epub 2019 Feb 7.

Assistant Professor, Department of Periodontics and Community Sciences, College of Dentistry, King Khalid University, Abha, Kingdom of Saudi Arabia.

Objective: We aimed to determine if there was any association between geographic tongue (GT) and fissured tongue with ABO blood group among adult psoriasis patients in Saudi Arabia.

Study Design: This hospital-based cross-sectional study included 100 consecutive new adult patients diagnosed with psoriasis and 100 case-matched participants in the control group (nonpsoriatic). Sociodemographic and dermatologic parameters, intraoral lesions (GT and fissured tongue), and ABO blood grouping and immunoglobulins were recorded and evaluated using χ or Fisher's exact test. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oooo.2019.01.080DOI Listing
February 2019

Preparation, Characterization and In Vivo Evaluation of Cyclosporine Cationic Liposomes for the Treatment of Psoriasis.

J Liposome Res 2019 Mar 21:1-25. Epub 2019 Mar 21.

a National Institute of Pharmaceutical Education and Research Hyderabad , Hyderabad , 500029 India.

Cyclosporine (CYC), a calcineurin inhibitor acts specifically on T-cells and is one of the most effective treatment options for psoriasis. Systemic administration of the drug has been associated with dose-dependent toxic effects, while its topical delivery is a challenging task due to unfavourable physicochemical properties of drug. The aim of the present study is to develop and evaluate the efficacy of topical liposomal gel containing CYC loaded cationic liposomal nanocarriers in imiquimod induced psoriatic plaque model. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/08982104.2019.1
Publisher Site
http://dx.doi.org/10.1080/08982104.2019.1593449DOI Listing
March 2019
7 Reads

Safety and efficacy of halobetasol propionate lotion 0.01% in the treatment of moderate to severe plaque psoriasis: a pooled analysis of 2 phase 3 studies.

Cutis 2018 Feb;102(2):111-116

Bausch Health, Petaluma, California, USA.

Potent topical corticosteroids (TCSs) are the mainstay of psoriasis treatment. Safety concerns have limited use to 2 to 4 weeks. The objective of our study was to investigate the safety and efficacy of once-daily halobetasol propionate (HP) lotion 0. Read More

View Article

Download full-text PDF

Source
February 2018
2 Reads

Psoriasis treatment in patients with sickle cell disease.

Cutis 2018 Feb;102(2):93-94

Department of Dermatology, The University of Tennessee Health Science Center, Memphis, USA.

Plaque psoriasis is a chronic inflammatory disease driven by the proliferation of T cells and the production of several immunomodulators such as tumor necrosis factor (TNF) α. Tumor necrosis factor α plays a key role in multiple inflammatory conditions, including psoriatic arthritis, rheumatoid arthritis, and hidradenitis suppurativa. We present a patient with plaque psoriasis and sickle cell disease who began treatment with the TNF-α inhibitor adalimumab. Read More

View Article

Download full-text PDF

Source
February 2018
8 Reads

Efficacy and safety of guselkumab, administered with a novel patient-controlled injector (One-Press), for moderate-to-severe psoriasis: results from the phase 3 ORION study.

J Dermatolog Treat 2019 Mar 19:1-8. Epub 2019 Mar 19.

g Department of Dermatology, Venereology and Allergology , Wroclaw Medical University , Wrocław , Poland.

Objectives: Guselkumab, an interleukin-23 antagonist, is approved for self-administration with the UltraSafe Plus™ syringe to treat moderate-to-severe plaque-type psoriasis. We evaluated the efficacy, safety, pharmacokinetics, and acceptability of guselkumab administered using a novel patient-controlled injector (One-Press) in psoriasis patients.

Materials And Methods: This Phase 3, multicentre, double-blind, placebo-controlled study (ORION, Clinicaltrials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/09546634.2019.1587145DOI Listing
March 2019
5 Reads

Biological treatments for paediatric psoriasis : a retrospective observational study on biological drug survival in daily practice in childhood psoriasis.

J Eur Acad Dermatol Venereol 2019 Mar 18. Epub 2019 Mar 18.

Service de Dermatologie, Hôpital Victor Dupouy, Argenteuil, France.

Background: Three biotherapies - etanercept, adalimumab and ustekinumab - are licensed in childhood psoriasis. The few data available on their efficacy and tolerance are mainly derived from industry trials. However, biological drug survival impacts long-term performance in real-life settings. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jdv.15579DOI Listing
March 2019
2 Reads

Halobetasol 0.01%/Tazarotene 0.045% Fixed-combination Lotion in the Treatment of Plaque Psoriasis: Sensitization and Irritation Potential.

J Clin Aesthet Dermatol 2019 Jan 1;12(1):11-15. Epub 2019 Jan 1.

Dr. Del Rosso is with JDR Dermatology Research/Thomas Dermatology in Las Vegas, Nevada.

Psoriasis is a chronic inflammatory skin disorder often managed with topical therapy. However, the most widely used treatments, including topical corticosteroids and tazarotene, can cause limiting skin irritation, contact sensitization, and/or present long-term safety concerns. Recently, clinical data on a new fixed combination of halobetasol 0. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405249PMC
January 2019
2 Reads

The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature.

Dermatol Ther (Heidelb) 2019 Mar 16. Epub 2019 Mar 16.

The Dermatology Centre, Salford Royal NHS Foundations Trust, The University of Manchester, Manchester Academic Health Science Centre, Manchester, UK.

Introduction: We review the literature evaluating certolizumab in psoriasis and report our experience of treatment outcomes in a joint dermatology and rheumatology clinic.

Methods: Patients with concomitant psoriatic arthritis (PsA) and psoriasis who had been commenced on certolizumab were included within our retrospective review. Data was collected for patient demographics, Patient Area and Severity Index (PASI), Dermatology Life Quality Index (DLQI) and previous treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13555-019-0290-5DOI Listing
March 2019
3 Reads

A prospective multi-center study assessing effectiveness and safety of secukinumab in a real-life setting in 158 patients.

J Am Acad Dermatol 2019 Mar 11. Epub 2019 Mar 11.

University General Hospital of Valencia, Dermatology Department.

Background: Secukinumab is a first-in-class IL-17A monoclonal antibody that has demonstrated an excellent safety and efficacy profile in Phase III studies.

Objectives: To evaluate the effectiveness of secukinumab in daily clinical practice and to understand the clinical and epidemiological characteristics of patients treated with secukinumab in clinical settings.

Methods: This multi-center prospective observational study recruited adult patients with moderate-to-severe plaque psoriasis from 12 Spanish hospitals between January and December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jaad.2019.02.062DOI Listing
March 2019
7 Reads

Observational study on Swedish plaque psoriasis patients receiving narrowband-UVB treatment show decreased S100A8/A9 protein and gene expression levels in lesional psoriasis skin but no effect on S100A8/A9 protein levels in serum.

PLoS One 2019 13;14(3):e0213344. Epub 2019 Mar 13.

Department of Clinical and Experimental Medicine, Faculty of Medicine and Health Sciences, Linköping University, Linköping, Sweden.

S100A8 and S100A9 proteins are highly upregulated in patients with psoriasis and have been proposed as potential biomarkers for psoriasis. The present study was designed to analyze the effect of narrowband ultraviolet B therapy on these proteins. S100A8, S100A9 gene expression and S100A8/A9 heterocomplex protein levels were analyzed in lesional and non-lesional skin before and after narrowband-UVB treatment in patients with chronic plaque type psoriasis. Read More

View Article

Download full-text PDF

Source
http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0213344PLOS
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6415841PMC
March 2019
2 Reads

A novel ultraviolet B home phototherapy system: Efficacy, tolerability, adherence, and satisfaction.

Dermatol Online J 2019 Feb 15;25(2). Epub 2019 Feb 15.

Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, North Carolina.

Background: Phototherapy is effective in treating psoriasis and other skin conditions. However, clinic-based phototherapy can be time-consuming, expensive, and inconvenient. Conventional home phototherapy addresses many hurdles, but has other limitations. Read More

View Article

Download full-text PDF

Source
February 2019
6 Reads

Sleep disorders in patients with psoriasis: a cross-sectional study using non-polysomnographical methods.

Sleep Breath 2019 Mar 11. Epub 2019 Mar 11.

Department of Dermatology, Faculty of Medicine, Bozok University, 66200, Yozgat, Turkey.

Background: Psoriasis is a chronic inflammatory skin disease which can cause sleep disturbances due to the disease itself or due to its complications. In this study, we aimed to analyze the array of sleep disturbances caused by psoriasis and to evaluate the interaction between the quality of sleep and the duration and severity of psoriasis.

Methods: Study subjects included 60 patients with plaque psoriasis and 60 sex- and age-matched controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11325-019-01820-8DOI Listing
March 2019
1 Read

Checklist for the Systemic Treatment of Psoriasis Using Biologics: A Delphi Study.

J Cutan Med Surg 2019 Mar 10:1203475419833605. Epub 2019 Mar 10.

2 Department of Medicine, University of Ottawa, Canada.

Background:: Despite the complexity of psoriasis treatment using biologic therapy, there does not exist a standardized synoptic reporting form for the initiation of this population. The purpose of this study was to use a modified Delphi approach to develop a standard checklist for the standardized documentation of patients receiving systemic biologic therapy for psoriasis.

Methods:: A modified Delphi survey was conducted over 3 rounds (February 2017 through January 2018). Read More

View Article

Download full-text PDF

Source
http://journals.sagepub.com/doi/10.1177/1203475419833605
Publisher Site
http://dx.doi.org/10.1177/1203475419833605DOI Listing
March 2019
21 Reads

A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis.

Actas Dermosifiliogr 2019 Mar 6. Epub 2019 Mar 6.

Eli Lilly and Company, Madrid, España.

Background And Objectives: Psoriasis is a chronic inflammatory skin disease with an estimated prevalence in Spain of 2.3% of the population. Approximately 30% of patients have moderate-to-severe forms. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ad.2018.10.017DOI Listing
March 2019
1 Read

Immunogenicity of Guselkumab Is Not Clinically Relevant in Patients with Moderate-to-Severe Plaque Psoriasis.

J Invest Dermatol 2019 Mar 6. Epub 2019 Mar 6.

Janssen Research & Development, LLC, Spring House, PA, USA.

In pivotal Phase-3 studies (VOYAGE-1, VOYAGE-2), patients (N=1,829) with moderate-to-severe plaque psoriasis were randomized to subcutaneous guselkumab 100mg (Weeks0, 4, then every-8-weeks), placebo with guselkumab crossover at Week16, or adalimumab with guselkumab crossover at Week28 or Week52. The design of VOYAGE-2 incorporated a randomized withdrawal and retreatment period for patients who achieved ≥90% improvement in the Psoriasis Area and Severity Index (PASI) score at Week28. To assess guselkumab immunogenicity, we evaluated sera for anti-drug antibodies (ADA), systemic exposure (serum drug concentrations), efficacy (Investigator's Global Assessment, PASI), and safety (injection-site reactions). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.jid.2019.02.018DOI Listing
March 2019
5 Reads